Search Results

You are looking at 91 - 100 of 1,088 items for :

  • "Lung cancer" x
  • Refine by Access: All x
Clear All
Full access

Perioperative Systemic Therapy for Resectable Non–Small Cell Lung Cancer

Bharathi Muthusamy, Pradnya D. Patil, and Nathan A. Pennell

Lung cancer accounts for the most deaths of any malignancy worldwide. 1 Non–small cell lung cancers (NSCLCs) constitute approximately 85% of all lung cancers. Most people with NSCLC are diagnosed at a metastatic or locally advanced stage, but

Full access

Similar Efficacy Observed for First-Line Immunotherapy in Racial/Ethnic Minority Patients With Metastatic NSCLC

Matthew Lee, Jianyou Liu, Emily Miao, Shuai Wang, Frank Zhang, John Wei, Julie Chung, Xiaonan Xue, Balazs Halmos, H. Dean Hosgood, and Haiying Cheng

Background Lung cancer is the leading cause of cancer-related mortality in the United States, but survival has improved over the last decade, largely driven by increased screening, identification of actionable driver alterations, use of

Full access

VATS Versus Open Surgery for Lung Cancer Resection: Moving Toward a Minimally Invasive Approach

Jacob Klapper and Thomas A. D’Amico

disease-free or locoregional recurrence-free survival in clinical stage I lung cancers treated using VATS or thoracotomy. Similarly, Sugi et al, 10 in a prospective randomized study of 100 consecutive patients with clinical stage IA non-small cell lung

Full access

Modification and Implementation of NCCN Guidelines™ on Non–Small Cell Lung Cancer in the Middle East and North Africa Region

Abdul-Rahman Jazieh, Hanaa Bamefleh, Ahmet Demirkazik, Rabab Mohamed Gaafar, Fady B. Geara, Mansur Javaid, Jamal Khader, Kian Khodadad, Walid Omar, Ahmed Saadeddin, Hassan Al Sabe, Mohammad Behgam Shadmehr, Amgad El Sherif, Najam Uddin, Mohammad Jahanzeb, and David Ettinger

L ung cancer is the leading cancer worldwide; not only in incidence but also in cancer-related death, with approximately 1.2 million cases diagnosed worldwide and 18% of cancer deaths related to lung cancer. 1 , 2 In the United States, lung

Full access

Novel Systemic Therapies for Small Cell Lung Cancer

Charles M. Rudin, Christine L. Hann, Craig D. Peacock, and D. Neil Watkins

Medical Research Institute (CMR). References 1. Jemal A Siegel R Ward E . Cancer statistics, 2007 . CA Cancer J Clin 2007 ; 57 : 43 – 66 . 2. Alberg AJ Brock MV Samet JM . Epidemiology of lung cancer: looking to the future

Full access

NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 1.2020

Featured Updates to the NCCN Guidelines

David S. Ettinger, Douglas E. Wood, Charu Aggarwal, Dara L. Aisner, Wallace Akerley, Jessica R. Bauman, Ankit Bharat, Debora S. Bruno, Joe Y. Chang, Lucian R. Chirieac, Thomas A. D’Amico, Thomas J. Dilling, Michael Dobelbower, Scott Gettinger, Ramaswamy Govindan, Matthew A. Gubens, Mark Hennon, Leora Horn, Rudy P. Lackner, Michael Lanuti, Ticiana A. Leal, Jules Lin, Billy W. Loo Jr, Renato G. Martins, Gregory A. Otterson, Sandip P. Patel, Karen L. Reckamp, Gregory J. Riely, Steven E. Schild, Theresa A. Shapiro, James Stevenson, Scott J. Swanson, Kurt W. Tauer, Stephen C. Yang, Kristina Gregory, OCN, and Miranda Hughes

be able to: Integrate into professional practice the updates to the NCCN Guidelines for Non–Small Cell Lung Cancer Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Non–Small Cell Lung Cancer Disclosure

Full access

Non–Small Cell Lung Cancer

UCSF Helen Diller Family Comprehensive Cancer Center

Lung cancer is the leading cause of cancer-related death in both men and women in the United States. An estimated 213,380 new cases (114,760 men and 98,620 women) of lung and bronchus cancer will be diagnosed in 2007, and 160,390 deaths (89,510 in men, 70,880 in women) are estimated to occur because of the disease. Non-small cell lung cancer (NSCLC) accounts for 80% to 85% of all lung cancer cases and includes 3 major types: (1) adenocarcinoma; (2) squamous cell (epidermoid) carcinoma; and (3) large-cell carcinoma. Adenocarcinoma is the most common type of lung cancer seen in the United States and is also the most frequently occurring cell type in nonsmokers. Important updates to the 2008 guidelines on NSCLC include the addition of tables on drugs and dosing information on chemotherapy regimens for adjuvant therapy.

For the most recent version of the guidelines, please visit

Full access

Management of EGFR Mutation–Positive Non–Small Cell Lung Cancer

Rogerio A. Lilenbaum and Leora A. Horn

The identification of molecular targets and the development of agents to treat those targets has changed the paradigm for the management of non–small cell lung cancer (NSCLC). “The progress in NSCLC has been absolutely amazing. EGFR and KRAS

Full access

Lung Cancer: Beyond the Guidelines

Gregory P. Kalemkerian

Full access

Where Your Data Is Going and Where It's Been

Jane M. Quigley

, prevalence, and treatment patterns is more important than ever given the growing costs of health care. Table 1 shows how integrating physician, ICD-9 code, and specialty pharmacy data is critical in understanding patient care and drug use for lung cancer